Heron Therapeutics (NASDAQ:HRTX) appointed three new directors to the board, including Kevin Kotler, a renowned healthcare investor, founder and portfolio manager of Broadfin Capital. Mr. Kotler has over 30 years of...
Heron Therapeutics (NASDAQ:HRTX) resubmitted its NDA for HTX-011 – a dual-acting combination of the local anesthetic bupivacaine and the nonsteroidal anti-inflammatory drug, meloxicam – to the FDA. The resubmission was...